148 related articles for article (PubMed ID: 27318641)
1. An aqueous normal-phase chromatography coupled with tandem mass spectrometry method for determining unbound brain-to-plasma concentration ratio of AZD1775, a Wee1 kinase inhibitor, in patients with glioblastoma.
Wu J; Sanai N; Bao X; LoRusso P; Li J
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():25-32. PubMed ID: 27318641
[TBL] [Abstract][Full Text] [Related]
2. Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry.
Bao X; Wu J; Sanai N; Li J
J Pharm Biomed Anal; 2019 Mar; 166():197-204. PubMed ID: 30660034
[TBL] [Abstract][Full Text] [Related]
3. Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.
Li J; Wu J; Bao X; Honea N; Xie Y; Kim S; Sparreboom A; Sanai N
Clin Cancer Res; 2017 Dec; 23(24):7454-7466. PubMed ID: 28928160
[No Abstract] [Full Text] [Related]
4. Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors.
Jiang J; Bao X; Yue Y; Schiff D; Bindra R; Li J
Biomed Chromatogr; 2022 Dec; 36(12):e5478. PubMed ID: 35938683
[TBL] [Abstract][Full Text] [Related]
5. A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor.
Bao X; Wu J; Sanai N; Li J
J Pharm Anal; 2018 Feb; 8(1):20-26. PubMed ID: 29568664
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.
Do K; Wilsker D; Ji J; Zlott J; Freshwater T; Kinders RJ; Collins J; Chen AP; Doroshow JH; Kummar S
J Clin Oncol; 2015 Oct; 33(30):3409-15. PubMed ID: 25964244
[TBL] [Abstract][Full Text] [Related]
7. Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.
Sanai N; Li J; Boerner J; Stark K; Wu J; Kim S; Derogatis A; Mehta S; Dhruv HD; Heilbrun LK; Berens ME; LoRusso PM
Clin Cancer Res; 2018 Aug; 24(16):3820-3828. PubMed ID: 29798906
[No Abstract] [Full Text] [Related]
8. Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Sparidans RW; Wang Y; Schinkel AH; Schellens JHM; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():167-172. PubMed ID: 30396050
[TBL] [Abstract][Full Text] [Related]
9. A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study.
Du P; Guan Y; An Z; Li P; Liu L
Analyst; 2019 Sep; 144(18):5462-5471. PubMed ID: 31380858
[TBL] [Abstract][Full Text] [Related]
10. Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry.
Li W; Perpinioti N; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122098. PubMed ID: 32278292
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies.
Maher HM; Alzoman NZ; Shehata SM
J Pharm Biomed Anal; 2016 May; 124():216-227. PubMed ID: 26966895
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
Liu X; Li W; Zhang Y; Jiang Y; Zhao Q; Zhong D
J Pharm Biomed Anal; 2019 Nov; 176():112735. PubMed ID: 31394305
[TBL] [Abstract][Full Text] [Related]
13. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.
de Gooijer MC; Buil LCM; Beijnen JH; van Tellingen O
Invest New Drugs; 2018 Jun; 36(3):380-387. PubMed ID: 29147815
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies.
Xu Y; Fang W; Zeng W; Leijen S; Woolf EJ
Anal Bioanal Chem; 2012 Dec; 404(10):3037-48. PubMed ID: 23099526
[TBL] [Abstract][Full Text] [Related]
15. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
Moreno JM; Wojnicz A; Steegman JL; Cano-Abad MF; Ruiz-Nuño A
Biomed Chromatogr; 2013 Apr; 27(4):502-8. PubMed ID: 23034891
[TBL] [Abstract][Full Text] [Related]
16. Development of simple and rapid LC-MS/MS method for determination of celecoxib in human plasma and its application to bioequivalence study.
Park MS; Shim WS; Yim SV; Lee KT
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 902():137-41. PubMed ID: 22771234
[TBL] [Abstract][Full Text] [Related]
17. Sensitive liquid chromatography/tandem mass spectrometry method for the determination of the lipophilic antipsychotic drug chlorpromazine in rat plasma and brain tissue.
Zhang G; Terry AV; Bartlett MG
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jul; 854(1-2):68-76. PubMed ID: 17452027
[TBL] [Abstract][Full Text] [Related]
18. Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.
de Bruijn P; Moghaddam-Helmantel IM; de Jonge MJ; Meyer T; Lam MH; Verweij J; Wiemer EA; Loos WJ
J Pharm Biomed Anal; 2009 Dec; 50(5):977-82. PubMed ID: 19628352
[TBL] [Abstract][Full Text] [Related]
19. Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.
Rood JJM; van Hoppe S; Schinkel AH; Schellens JHM; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2016 Jan; 118():123-131. PubMed ID: 26540627
[TBL] [Abstract][Full Text] [Related]
20. LC-MS/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors.
Zhong B; Campagne O; Salloum R; Purzner T; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122254. PubMed ID: 32615532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
